Merck (MRK) PT Raised to $132 at BofA Securities

Merck (MRK) PT Raised to $135 at BMO Capital

February 4, 2026 5:43 AM EST

BMO Capital analyst Evan David Seigerman raised the price target on Merck (NYSE: MRK) to $135.00 (from $130.00) while maintaining a Outperform rating.

The analyst comments "Potential Keytruda IP protection through November 2029 could further smooth revenue declines associated with the Keytruda LOE. On today's call,... More

Merck shares fall as 2026 guidance disappoints despite solid Q4 results

February 3, 2026 6:48 AM EST

Investing.com -- Merck & Co. (NYSE: MRK) shares have dropped 1.6% premarket on Tuesday after the pharmaceutical giant issued 2026 guidance below analyst expectations, overshadowing solid fourth-quarter results that met earnings forecasts and slightly exceeded revenue estimates.

The company reported fourth-quarter adjusted earnings of $2.04 per share, matching analyst expectations, while revenue rose 5% to $16.4 billion, surpassing the consensus estimate of $16.18 billion. Revenue... More

Merck's 2026 outlook clouds upbeat fourth-quarter results

February 3, 2026 6:34 AM EST

By Michael Erman and Mariam Sunny

Feb 3 (Reuters) - Merck & Co on Tuesday forecast 2026 sales and profits below Wall Street estimates, saying the imminent loss of exclusivity on diabetes drug Januvia and other legacy medicines will impact more than analysts expect.

The weaker-than-anticipated outlook overshadowed a solid fourth quarter, in which the U.S. drugmaker beat profit and sales expectations on strong demand for its blockbuster cancer immunotherapy Keytruda.

The company expects 2026 revenue of $65.5 billion to $67.0 billion, with the top end below the average analyst estimate of $67.6 billion, according to LSEG data.

BMO Capital analyst Evan Seigerman said... More

Merck (MRK) Reports In-Line Q4 EPS; offers guidance

February 3, 2026 6:31 AM EST

Merck (NYSE: MRK) reported Q4 EPS of $2.04, in-line with the analyst estimate of $2.04. Revenue for the quarter came in at $16.4 billion versus the consensus estimate of $16.18 billion.

GUIDANCE:

Merck sees FY2026 EPS of $5.00-$5.15, versus the consensus of $5.63. Merck sees... More

Merck preview: focus on post-Keytruda growth path

February 2, 2026 10:00 PM EST

Investing.com -- Merck (NYSE: MRK) fourth-quarter results are expected to frame how the company plans to manage looming Keytruda declines and reset its growth narrative into 2026.

BMO said the quarter should mark an inflection point, with management likely to lay out early revenue expectations for several new launches that are central to Mercks longer-term outlook.

Those include enlicitide, Ohtuvayre and Enflonsia, which BMO... More

Merck (MRK) call put ratio 2.1 calls to 1 put into quarter results

February 2, 2026 10:26 AM EST

Merck (NYSE: MRK) February 6 weekly call option implied volatility is at 57, February is at 36; compared to its 52-week range of 22 to 55. Call put ratio 2.1 calls to 1 put into the expected release of quarter results before the bell on February 3.

... More

Merck (MRK) call put ratio 1.7 calls to 1 put into quarter results

February 2, 2026 5:07 AM EST

Merck (NYSE: MRK) February 6 weekly 110 straddle priced for a move of 4.5%. Call put ratio 1.7 calls to 1 put into the expected release of quarter results before the bell on February 3.

... More